Advertisement

Hepatic resection prolongs overall survival in the selected patients with nasopharyngeal carcinoma liver metastases

  • Author Footnotes
    1 These authors contributed equally to this work.
    Yun Feng
    Footnotes
    1 These authors contributed equally to this work.
    Affiliations
    Department of Hepatic Surgery, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, 200032, China
    Search for articles by this author
  • Author Footnotes
    1 These authors contributed equally to this work.
    Yi-Ming Zhao
    Footnotes
    1 These authors contributed equally to this work.
    Affiliations
    Department of Hepatic Surgery, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, 200032, China
    Search for articles by this author
  • Author Footnotes
    1 These authors contributed equally to this work.
    Wei-Wei Li
    Footnotes
    1 These authors contributed equally to this work.
    Affiliations
    Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, 200032, China
    Search for articles by this author
  • Xi-Gan He
    Affiliations
    Department of Hepatic Surgery, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, 200032, China
    Search for articles by this author
  • Chang-Ming Zhou
    Affiliations
    Department of Cancer Prevention, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, 200032, China
    Search for articles by this author
  • Qi Pan
    Affiliations
    Department of Hepatic Surgery, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, 200032, China
    Search for articles by this author
  • An-Rong Mao
    Affiliations
    Department of Hepatic Surgery, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, 200032, China
    Search for articles by this author
  • Wei-Ping Zhu
    Affiliations
    Department of Hepatic Surgery, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, 200032, China
    Search for articles by this author
  • Chao-Su Hu
    Affiliations
    Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, 200032, China
    Search for articles by this author
  • Lu Wang
    Correspondence
    Corresponding author. Department of Hepatic Surgery, Fudan University Shanghai Cancer Center, No.270 Dong'an Road, Xuhui District, Shanghai, 200032, China.
    Affiliations
    Department of Hepatic Surgery, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, 200032, China
    Search for articles by this author
  • Author Footnotes
    1 These authors contributed equally to this work.

      Abstract

      Background

      The role of surgery in nasopharyngeal carcinoma liver metastases (NCLM) remains elusive, and the current application is limited. We aim to investigate whether hepatic resection (HR) of NCLM improves survival compared with non-hepatic resection (NHR) treatment.

      Methods

      One hundred and thirty-three patients with NCLM from 2007 to 2017 were divided into two groups. Propensity score matching (PSM) analysis was used to compare the clinical outcomes.

      Results

      After PSM the median overall survival (OS) and the 1, 3 and 5-year OS rates in HR group were 32.60 months, 86.2%, 37.3% and 37.3%, respectively; while for NHR group these values were 19.57 months, 61.5%, 12.9% and 2.9%, respectively (P = 0.008). Multivariate analysis indicated hepatitis B virus infection (P = 0.029) and hepatic resection (P = 0.018) were independent prognostic factors.

      Conclusion

      Our study revealed that hepatectomy yields a survival benefit safely compared with systemic treatments, especially for patients with the size of largest metastasis < 5 cm, unilobar distribution of liver tumor and received unanatomical hepatectomy.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Surgical Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Sung H.
        • Ferlay J.
        • Siegel R.
        • Laversanne M.
        • Soerjomataram I.
        • Jemal A.
        • et al.
        Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries.
        CA A Cancer J Clin. 2021; 71: 209-249
        • Chen Y.
        • Chan A.
        • Le Q.
        • Blanchard P.
        • Sun Y.
        • Ma J.
        Nasopharyngeal carcinoma.
        Lancet (London, England). 2019; 394: 64-80
        • Foo K.
        • Tan E.
        • Leong S.
        • Wee J.
        • Tan T.
        • Fong K.
        • et al.
        Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type.
        Ann Oncol : official journal of the European Society for Medical Oncology. 2002; 13: 150-156
        • Peng C.
        • Zhou C.
        • Li G.
        • Li H.
        • Shi L.
        Hepatic artery infusion pump for nasopharyngeal carcinoma with liver metastasis.
        Clin Exp Metastasis. 2020; 37: 333-339
        • Qu W.
        • Li S.
        • Zhang M.
        • Qiao Q.
        Pattern and prognosis of distant metastases in nasopharyngeal carcinoma: a large-population retrospective analysis.
        Cancer Med. 2020; 9: 6147-6158
        • Jin Y.
        • Shi Y.
        • Cai X.
        • Xia X.
        • Cai Y.
        • Cao Y.
        • et al.
        Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma.
        J Cancer Res Clin Oncol. 2012; 138: 1717-1725
        • Zhang L.
        • Huang Y.
        • Hong S.
        • Yang Y.
        • Yu G.
        • Jia J.
        • et al.
        Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial.
        Lancet (London, England). 2016; 388: 1883-1892
        • Liu Z.
        • Chen Y.
        • Su Y.
        • Hu X.
        • Peng X.
        Nasopharyngeal carcinoma: clinical achievements and Considerations among treatment options.
        Front Oncol. 2021; 11635737
        • Ma B.
        • Lim W.
        • Goh B.
        • Hui E.
        • Lo K.
        • Pettinger A.
        • et al.
        Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the mayo clinic phase 2 Consortium (NCI-9742).
        J Clin Oncol : official journal of the American Society of Clinical Oncology. 2018; 36: 1412-1418
        • Hsu C.
        • Lee S.
        • Ejadi S.
        • Even C.
        • Cohen R.
        • Le Tourneau C.
        • et al.
        Safety and antitumor activity of pembrolizumab in patients with programmed death-Ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study.
        J Clin Oncol : official journal of the American Society of Clinical Oncology. 2017; 35: 4050-4056
        • Tian Y.
        • Zeng L.
        • Wang F.
        • Liu S.
        • Guan Y.
        • Lu T.
        • et al.
        Prognostic factors in nasopharyngeal carcinoma with synchronous liver metastasis: a retrospective study for the management of treatment.
        Radiat Oncol. 2013; 8: 272
        • Huang J.
        • Li Q.
        • Zheng Y.
        • Shen J.
        • Li B.
        • Zou R.
        • et al.
        Partial hepatectomy for liver metastases from nasopharyngeal carcinoma: a comparative study and review of the literature.
        BMC Cancer. 2014; 14: 818
        • Goéré D.
        • Elias D.
        Resection of liver metastases from non-colorectal non-endocrine primary tumours.
        Eur J Surg Oncol : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2008; 34: 281-288
        • Liu W.
        • Yu B.
        • Luo Y.
        • Li J.
        • Yuan X.
        • Wu S.
        • et al.
        Survival benefit of induction chemotherapy for locally advanced nasopharyngeal carcinoma: prognosis based on a new risk estimation model.
        BMC Cancer. 2021; 21: 639
        • D'Agostino Jr., R.B.
        Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group.
        Stat Med. 1998; 17: 2265-2281
        • Loux T.M.
        Randomization, matching, and propensity scores in the design and analysis of experimental studies with measured baseline covariates.
        Stat Med. 2015; 34: 558-570
        • Karnofsky D.
        • Burchenal J.
        Present status of clinical cancer chemotherapy.
        Am J Med. 1950; 8: 767-788
        • Kishi Y.
        • Abdalla E.
        • Chun Y.
        • Zorzi D.
        • Madoff D.
        • Wallace M.
        • et al.
        Three hundred and one consecutive extended right hepatectomies: evaluation of outcome based on systematic liver volumetry.
        Ann Surg. 2009; 250: 540-548
        • Zorzi D.
        • Laurent A.
        • Pawlik T.
        • Lauwers G.
        • Vauthey J.
        • Abdalla E.
        Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases.
        Br J Surg. 2007; 94: 274-286
        • Feng Y.
        • He X.
        • Zhou C.
        • Zhang Q.
        • Huang S.
        • Li Z.
        • et al.
        Comparison of hepatic resection and systemic treatment of breast cancer liver metastases: a propensity score matching study.
        Am J Surg. 2020; 220: 945-951
        • Schwarz C.
        • Kaczirek K.
        • Bodingbauer M.
        Liver resection for non-colorectal metastases.
        Eur Surg : ACA : Acta chirurgica Austriaca. 2018; 50: 113-116
        • Yin J.
        • Li N.
        • Han Y.
        • Xue J.
        • Deng Y.
        • Shi J.
        • et al.
        Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study.
        J Clin Oncol : official journal of the American Society of Clinical Oncology. 2013; 31: 3647-3655
        • Huang G.
        • Lau W.
        • Wang Z.
        • Pan Z.
        • Yuan S.
        • Shen F.
        • et al.
        Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial.
        Ann Surg. 2015; 261: 56-66
        • Li Z.
        • Li S.
        • Tao H.
        • Zhan Y.
        • Ni K.
        • Gong J.
        • et al.
        Higher titer hepatitis B core antibody predicts a higher risk of liver metastases and worse survival in patients with colorectal cancer.
        World J Surg Oncol. 2021; 19: 251
        • Xu Y.
        • Huang T.
        • Mao M.
        • Zhai J.
        • Chen J.
        Metastatic Patterns and Prognosis of de novo Metastatic Nasopharyngeal Carcinoma in the United States.
        Laryngoscope. 2021; 131: E1130-E1138
        • Li W.
        • Bai Y.
        • Wu M.
        • Shen L.
        • Shi F.
        • Sun X.
        • et al.
        Combined CT-guided radiofrequency ablation with systemic chemotherapy improves the survival for nasopharyngeal carcinoma with oligometastasis in liver: propensity score matching analysis.
        Oncotarget. 2017; 8: 52132-52141
        • Zeng Z.
        • Shen L.
        • Wang Y.
        • Shi F.
        • Chen C.
        • Wu M.
        • et al.
        A nomogram for predicting survival of nasopharyngeal carcinoma patients with metachronous metastasis.
        Medicine. 2016; 95e4026
        • Ivey G.
        • Johnston F.
        • Azad N.
        • Christenson E.
        • Lafaro K.
        • Shubert C.
        Current surgical management strategies for colorectal cancer liver metastases.
        Cancers. 2022; 14
        • Cassar N.
        • Geoghegan J.
        • Hoti E.
        Shifting concepts in the management of colorectal liver metastases.
        Surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland. 2022; S1479-666X: 00200-00206
        • Deng G.
        • Li H.
        • Jia G.
        • Fang D.
        • Tang Y.
        • Xie J.
        • et al.
        Parenchymal-sparing versus extended hepatectomy for colorectal liver metastases: a systematic review and meta-analysis.
        Cancer Med. 2019; 8: 6165-6175
        • Andreou A.
        • Gloor S.
        • Inglin J.
        • Di Pietro Martinelli C.
        • Banz V.
        • Lachenmayer A.
        • et al.
        Parenchymal-sparing hepatectomy for colorectal liver metastases reduces postoperative morbidity while maintaining equivalent oncologic outcomes compared to non-parenchymal-sparing resection.
        Surgical oncology. 2021; 38101631
        • Mise Y.
        • Aloia T.
        • Brudvik K.
        • Schwarz L.
        • Vauthey J.
        • Conrad C.
        Parenchymal-sparing hepatectomy in colorectal liver metastasis improves salvageability and survival.
        Ann Surg. 2016; 263: 146-152
        • Wong L.
        • Sutton T.
        • Walker B.
        • Lopez C.
        • Kardosh A.
        • Eil R.
        • et al.
        Surgical and oncologic outcomes following repeat hepatic resection of colorectal liver metastasis: who benefits?.
        Am J Surg. 2021; 221: 1114-1118
        • Wong K.
        • Johnson D.
        • Hui E.
        • Lam R.
        • Ma B.
        • Chan A.
        Opportunities and challenges in combining immunotherapy and radiotherapy in head and neck cancers.
        Cancer Treat Rev. 2022; 105102361